5-amino-2-methylisoquinolin-1(2H)-one | 42792-97-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-amino-2-methylisoquinolin-1(2H)-one
• 英文别名: 5-Amino-2-methylisoquinolin-1-one
• CAS: 42792-97-2
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD00489148
• 分子量: 174.202
• InChiKey: RGOCAJHJUPXFMV-UHFFFAOYSA-N

物化性质

• 熔点：
  138-140 °C
• 沸点：
  393.4±42.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-amino-2-methylisoquinolin-1(2H)-one 在 吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 1-(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)-3-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)methyl)urea
  参考文献：
  名称：

  Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift

  摘要：

  Among a series of benzopyridone-based scaffolds investigated as human transient receptor potential vanilloid 1 (TRPV1) ligands, two isomeric benzopyridone scaffolds demonstrated a consistent and distinctive functional profile in which 2-oxo-1,2-dihydroquinolin-5-yl analogues (e.g., 2) displayed high affinity and potent antagonism, whereas 1-oxo-1,2-dihydroisoquinolin-5-yl analogues (e.g., 3) showed full agonism with high potency. Our computational models provide insight into the agonist-antagonist boundary of the analogues suggesting that the Arg557 residue in the S4-S5 linker might be important for sensing the agonist binding and transmitting signals. These results provide structural insights into the TRPV1 and the protein-ligand interactions at a molecular level.

  DOI：

  10.1021/acs.jmedchem.0c00982
• 作为产物：
  描述：

  5-硝基-1(2H)-异喹啉酮 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 23.5h， 生成 5-amino-2-methylisoquinolin-1(2H)-one
  参考文献：
  名称：

  Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift

  摘要：

  Among a series of benzopyridone-based scaffolds investigated as human transient receptor potential vanilloid 1 (TRPV1) ligands, two isomeric benzopyridone scaffolds demonstrated a consistent and distinctive functional profile in which 2-oxo-1,2-dihydroquinolin-5-yl analogues (e.g., 2) displayed high affinity and potent antagonism, whereas 1-oxo-1,2-dihydroisoquinolin-5-yl analogues (e.g., 3) showed full agonism with high potency. Our computational models provide insight into the agonist-antagonist boundary of the analogues suggesting that the Arg557 residue in the S4-S5 linker might be important for sensing the agonist binding and transmitting signals. These results provide structural insights into the TRPV1 and the protein-ligand interactions at a molecular level.

  DOI：

  10.1021/acs.jmedchem.0c00982

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LA MODULATION DE NR2F6
  申请人：TES PHARMA S R L

  公开号：WO2021170658A1

  公开（公告）日：2021-09-02

  The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

  本公开涉及能够调节NR2F6活性的化合物。本公开的化合物可用于预防及/或治疗与调节NR2F6活性相关疾病和障碍的方法。
• DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS
  申请人：Brotherton-Pleiss Christine E.

  公开号：US20110028502A1

  公开（公告）日：2011-02-03

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R a and R b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  化合物的公式I：或其药用盐，其中m、n、R1、R2、R3、R4、R5、Ra和Rb的定义如本文所述。还公开了制备这些化合物的方法以及利用这些化合物治疗与P2X7嘌呤受体相关的疾病的方法。
• DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS
  申请人：Berger Jacob

  公开号：US20100160373A1

  公开（公告）日：2010-06-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 and R a are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  公式I的化合物：或其药用盐，其中m，n，R1，R2，R3，R4，R5和Ra如本文所定义。还公开了制备这些化合物的方法以及利用这些化合物治疗与P2X7嘌呤受体相关的疾病的方法。
• Electron Impact Induced Loss of C-5/C-8 Substituents of 1,2,3,4-Tetrahydroisoquinolines, VI1): Synthesis and Mass Spectrometric Fragmentation of Dihydroindole Derivatives
  作者：Frank Knefeli、Klaus K. Mayer、W. Wiegrebe、Urs P. Schlunegger、Rolf Lauber

  DOI：10.1002/ardp.19903230305

  日期：——

  identical with that of m/z 146 from the C‐5 substituted tetrahydroisoquinolines 3, 6, 7, and 8 (scheme 2), so supporting our hypothesis of a rearrangement in M+ of tetrahydroisoquinolines1) prior to fragmentation, but not proving it. As the CID MIKE spectra of the tetrahydroisoquinolines 3, 6, 7, and 8 are not identical among each other we assume that a 1.3‐H‐shift takes places in their M+ in competition

  描述了 C-4 取代的二氢吲哚 25、31（方案 7）和 36（方案 8）的合成。- 来自 25 的 m/z 146 的 2. 无场区 (2. FFR) 中的 CID MIKE 光谱与来自 C-5 取代的四氢异喹啉 3、6、7 的 m/z 146 的光谱非常相似但不完全相同, 和 8（方案 2），因此支持了我们的假设，即四氢异喹啉在 M+ 中发生重排 1) 在断裂之前，但没有证明这一点。由于四氢异喹啉 3、6、7 和 8 的 CID MIKE 光谱彼此不同，我们假设它们的 M + 发生 1.3 - H - 位移以与上述重排竞争。
• Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof
  申请人：Intendis GmbH

  公开号：EP1982976A1

  公开（公告）日：2008-10-22

  The current invention describes novel synthetic routes and intermediates for the manufacture of anti-inflammatory agents of general formula VIII in which one of the groups X1, X2, X3 is selected from fluoro, chloro, bromo, hydroxy, methoxy, ethoxy, trifluoromethyl, amino whereas the other groups X1, X2, X3 have the meaning of a hydrogen atom, in which one of the groups Z1, Z2, Z3 is selected from -O-, -S-, -NH-, -N(-CH3)-, whereas the other groups Z1, Z2, Z3 have the meaning of a -CH2- group, and in which Ar is an aromatic group.

  当前发明描述了制造通式VIII的抗炎剂的新合成路线和中间体，其中X1、X2、X3组中的一个选择自氟、氯、溴、羟基、甲氧基、乙氧基、三氟甲基、氨基，而另外的X1、X2、X3组的含义为氢原子，其中Z1、Z2、Z3组中的一个选择自-O-、-S-、-NH-、-N(-CH3)-，而另外的Z1、Z2、Z3组的含义为-CH2-基团，Ar为芳香族基团。